G protein-coupled receptors of the Adhesion family (aGPCRs) comprise the second largest group within the GPCR realm with over 30 mammalian homologs. They contain a unique structure with unusually large extracellular domains (ECDs) holding many structural folds known to mediate cell-cell and cell-matrix interactions. Furthermore, aGPCRs undergo autoproteolytic cleavage at the GPCR proteolysis site (GPS), an integral portion of the GPCR autoproteolysis inducing (GAIN) domain. Thus far, it is largely unknown if and how self-cleavage affects aGPCR activation and signaling and how these signals may shape the physiological function of cells. Latrophilin, alternatively termed the calcium-independent receptor of α-latrotoxin (CIRL) constitutes a highly conserved, prototypic aGPCR and has been assigned roles in various biological processes such as synaptic development and maturation or the regulation of neurotransmitter release. The Drosophila melanogaster homolog dCIRL is found in numerous sensory neurons including the mechanosensory larval pentascolopidial chordotonal organs (CHOs), which rely on dCIRL function in order to sense mechanical cues and to modulate the mechanogating properties of present ionotropic receptors. This study reveals further insight into the broad distribution of dCirl expression throughout the larval central nervous system, at the neuromuscular junction (NMJ), as well as subcellular localization of dCIRL in distal dendrites and cilia of chordotonal neurons. Furthermore, targeted mutagenesis which disabled GPS cleavage of dCIRL left intracellular trafficking in larval CHOs unaffected and proved autoproteolysis is not required for dCIRL function in vivo. However, substitution of a threonine residue, intrinsic to a putative tethered agonist called Stachel that has previously been documented for several other aGPCRs, abrogated receptor function. Conclusively, while this uncovered the presence of Stachel in dCIRL, it leaves the question about the biological relevance of the predetermined breaking point at the GPS unanswered. In an independent approach, the structure of the “Inter-RBL-HRM” (IRH) region, the region linking the N-terminal Rhamnose-binding lectin-like (RBL) and the hormone receptor motif (HRM) domains of dCIRL, was analyzed. Results suggest random protein folding, excessive glycosylation, and a drastic expansion of the size of IRH. Therefore, the IRH might represent a molecular spacer ensuring a certain ECD dimension, which in turn may be a prerequisite for proper receptor function. Taken together, the results of this study are consistent with dCIRL’s mechanoceptive faculty and its role as a molecular sensor that translates mechanical cues into metabotropic signals through a yet undefined Stachel-dependent mechanism. / G-Protein-gekoppelte Rezeptoren der Adhäsions-Klasse (aGPCRs) bilden mit über 30 Homologen in Säugern die zweitgrößte Gruppe innerhalb des GPCR-Reichs. Sie teilen eine einzigartige Morphologie mit einer ungewöhnlich großen extrazellulären Domäne (ECD), welche meist vielfältige Strukturen enthält, die Zell-Zell- und Zell-Matrix-Interaktionen vermitteln. Weiterhin unterziehen sich aGPCRs einer autoproteolytischen Spaltung an der GPCR proteolysis site (GPS), die einen integralen Bestandteil der GPCR autoproteolysis inducing (GAIN) Domäne darstellt. Bisher ist weitestgehend unbekannt, ob und wie die Selbstspaltung Aktivierung und Signaltransduktion von aGPCRs beeinflusst und wie diese Signale die physiologische Zellfunktion modulieren. Latrophilin, oder auch der Kalzium-unabhängige Rezeptor für α-Latrotoxin (CIRL), stellt einen evolutiv stark konservierten, prototypischen aGPCR dar und spielt eine Rolle in verschiedenen biologischen Prozessen, darunter die Entwicklung und Reifung von Synapsen, sowie die Regulation der Neurotransmitterausschüttung. Zusätzlich ist dCIRL, das Latrophilinhomolog von Drosophila melanogaster, an der Wahrnehmung mechanischer Reize beteiligt und moduliert die Mechanosensitivität larvaler Chordotonalorgane (CHOs), indem es das mechanisch gesteuerte Verhalten vorliegender ionotroper Rezeptoren verändert. Die vorliegende Arbeit enthüllt weitere Erkenntnisse zur umfassenden Expression von dCirl im larvalen Zentralnervensystem, an der motorischen Endplatte (NMJ), und stellt erstmals dessen subzelluläre Lokalisation in distalen Dendriten und Zilien von Chordotonalneuronen dar. Außerdem zeigen Mutationsstudien mit ausgeschalteter Autoproteolyse an der GPS, dass diese für den intrazellulären Transport und die Rolle von dCIRL in larvalen CHOs in vivo von untergeordneter Bedeutung ist. Die Mutation eines Threonins, welches integraler Bestandteil eines möglichen gebundenen Agonisten Stachel, der kürzlich für einige andere aGPCRs beschrieben wurde, ist, verschlechtert jedoch drastisch die Rezeptorfunktion. Während dies die Existenz Stachels in dCIRL aufdeckt, bleibt die Frage nach der biologischen Bedeutung der vorgegebenen Bruchstelle an der GPS unbeantwortet. Zusätzlich wurde die Struktur der „Inter-RBL-HRM“ (IRH) Region von dCIRL, die die N-terminale Rhamnose-binding lectin-like (RBL) und die hormone receptor motif (HRM) Domänen verbindet, analysiert. Die Ergebnisse legen eine zufällige Proteinfaltung, starke Glykosylierung sowie riesige strukturelle Ausmaße von IRH nahe. Daher könnte die IRH einen molekularen Abstandhalter für dCIRL darstellen, der eine bestimmte Länge der ECD sicherstellt, was wiederum eine Voraussetzung für die Rezeptorfunktion sein könnte. Zusammen betrachtet sind die Ergebnisse dieser Arbeit vereinbar mit der mechanozeptiven Funktion von dCIRL und dessen Rolle als molekularer Sensor, der mechanische Reize mit Hilfe eines bisher unbekannten Stachel-abhängigen Mechanismus in metabotrope Signale umwandelt.

Actually, there is a strong incidence of psychiatric diseases, representing a 13% of total burden diseases and 450 million of people affected. The etiology of psychiatric diseases remains unknown. However, scientific evidences suggest a maldevelopment of nervous system (NS). The diagnosis is inaccurate, and international manuals (ICD-10 and DSM-IV) identify pathologies according to a list of symptoms but no underlying biological cause of disease. The aim of the thesis is to identify potential biomarkers -related to the development of NS- in peripheral blood of psychiatric patients diagnosed as different mental diseases, such as autism spectrum disorders (ASD), schizophrenia and bipolar disorders. It is intended to contribute with the improvement of diagnostic, prognostic and treatment of subjects. The thesis is divided into 4 chapters: 1) study of neurotrophins in ASD, where the results show the relationship of this family of molecules with the disease, 2) study of Latrophilin-3 (LPHN3) in the TEA, which was obtained in association with lower cognitive level of ASD, 3) study of the Eph-receptor A4 in the pathology of schizophrenia and bipolar disorder, results of which show no association, and finally 4) study of Ankyrin-3 (ANK3) in schizophrenia and bipolar disorder, which shown a relationship with bipolar disorder but not with schizophrenia. / Actualment, hi ha una forta incidència de les patologies psiquiàtriques, representant un 13% del total de les malalties i 450 milions de persones afectades. L’etiologia de les patologies psiquiàtriques és desconeguda. Tot i així, evidències científiques suggereixen un mal desenvolupament del sistema nerviós (SN). El diagnòstic és poc precís, i els manuals internacionals (ICD-10 i DSM-IV) identifiquen les patologies d’acord a un llistat de símptomes, però sense cap causa biològica subjacent de la patologia. L’objectiu de la tesi és la identificació de biomarcadors potencials –relacionats en el desenvolupament del SN- en sang perifèrica de pacients diagnosticats amb diferents patologies mentals, com ara els trastorns de l’espectre autista (TEA), esquizofrènia i desordres bipolars. És pretén contribuir amb la millora del diagnòstic, el pronòstic i el tractament de les persones que les pateixen. La tesi s’estructura en 4 capítols: 1) estudi de les neurotrofines en els TEA, on els resultats evidencien la relació d’aquesta família de molècules amb la patologia, 2) estudi de la Latrofilina-3 (LPHN3) en els TEA, on s’ha obtingut associació amb el nivell cognitiu més baix dels TEA, 3) estudi del receptor EPH A4 en les patologies d’esquizofrènia i desordres bipolars, resultats del qual no mostren associació i, per últim 4) estudi de la Ankirina-3 (ANK3) en l’esquizofrènia i els desordres bipolars, en el qual si que es troba una relació amb els desordres bipolars, però no amb l’esquizofrènia. / Actualmente, hay una fuerte incidencia de las patologías psiquiátricas, representando un 13% del total de las enfermedades y 450 millones de personas afectadas. La etiología de las patologías psiquiátricas es desconocida. Aún así, evidencias científicas sugieren un mal desarrollo del sistema nervioso (NS). El diagnóstico es poco preciso, y los manuales internacionales (ICD-10 y DSM-IV) identifican las patologías de acuerdo a un listado de síntomas, pero sin ninguna causa biológica subyacente de la patología. El objetivo de la tesis es la identificación de biomarcadores potenciales –relacionados con el desarrollo del SN- en sangre periférica de pacientes diagnosticados con diferentes patologías mentales, como son los trastornos del espectro autista (TEA), esquizofrenia y desordenes bipolares. Se pretende contribuir en la mejora del diagnóstico, el pronóstico i el tratamiento de las personas que las padecen. La tesis se estructura en 4 capítulos: 1) estudio de las neurotrofinas en los trastornos del espectro autista (TEA), en el cual los resultados evidencian la relación de esta familia de moléculas con la patología, 2) estudio de la Latrofilina-3 (LPHN3) en los TEA, donde se ha obtenido una asociación con el nivel cognitivo más bajo de los TEA, 3) estudio del receptor EPH A4 en las patologías de la esquizofrenia y los desordenes bipolares, resultados del cual no muestran asociación y, por último 4) estudio de la Ankirina-3 (ANK3) en la esquizofrenia y los desordenes bipolares, en el cual si que se ha encontrado una relación con los desordenes bipolares, pero no con la esquizofrenia.

No description available.

G proteins coupled receptors (GPCRs) play essential developmental roles with functions in all of the immune, olfactory sensory systems amongst other systems as well as exhibiting essential roles in the central and peripheral nervous system. GPCRs are also major targets of pharmaceutical drugs currently used to treat a vast number of conditions. Despite their clear importance, the function of many GPCRs is still obscure. Identifying the physiological role of more GPCRs provides a niche for more drugs to be developed and thus more conditions to be treated. The C.elegans lat-1 gene encodes the latrophilin vertebrate homolog; it is a member of the adhesion GPCR family and is structurally related to the flamingo/CELSR, an essential component of planar cell polarity pathway. This study aims to phenotypically characterise lat-1 mutants in C.elegans to provide insights into the physiological role of this important member of adhesion GPCRs. lat-1 mutants exhibit several morphological defects throughout development and during vulva development. Analysing the embryonic development of such mutants also identified an anterior-posterior polarity defect. The results implicate a second evolutionary conserved subfamily of adhesion GPCRs in the control of tissue polarity and morphogenesis.

<strong>Background:</strong> Our laboratory identified ELTD1, an orphan GPCR belonging to the adhesion GPCR family (aGPCR), as a novel regulator of angiogenesis and a potential anti-cancer therapeutic target. ELTD1 is normally expressed in both endothelial cells and vascular smooth muscle cells and expression is significantly increased in the tumour vasculature. The aim of this project was to analyse ELTD1's function in endothelial cells and its role in breast cancer. <strong>Method:</strong> 62 sequenced vertebrate genomes were interrogated for ELTD1 conservation and domain alterations. A phylogenetic timetree was assembled to establish time estimates for ELTD1's evolution. After ELTD1 silencing, mRNA array profiling was performed on primary human umbilical vein endothelial cells (HUVECs) and validated with qPCR and confocal microscopy. ELTD1's signalling was investigated by applying the aGPCR ‘Stinger/tethered-agonist Hypothesis'. For this, truncated forms of ELTD1 and peptides analogous to the proposed tethered agonist region were designed. FRET-based 2^nd messenger (Cisbio IP-1;cAMP) and luciferase-reporter assays (NFAT; NFÎoB; SRE; SRF-RE; CREB) were performed to establish canonical GPCR activation. To further investigate ELTD1's role in endothelial cells, ELTD1 was stably overexpressed in HUVECS. Functional angiogenesis assays and mRNA array profiling were then performed. To investigate ELTD1 in breast cancer, a panel of cell lines representative of all molecular subtypes were screened using qPCR. Furthermore, an exploratory pilot study was performed on matched primary and regional nodal secondary breast cancers (n=43) which were stained for ELTD1 expression. Staining intensity was then scored and compared with relapse free survival and overall survival. <strong>Results:</strong> ELTD1 arose 435 million years ago (mya) in bony fish and is present in all subsequent vertebrates. ELTD1 has 3 evolutionary variants of which 2 are most common: one variant with 3 EGFs and a variant with 2 EGFs. Additionally, ELTD1 may be ancestral to members of aGPCR family 2. HUVEC mRNA expression profiling after ELTD1 silencing showed upregulation of the mitochondrial citrate transporter SLC25A1, and ACLY which converts cytoplasmic citrate to Acetyl CoA, feeding fatty acid and cholesterol synthesis, and acetylation. A review of lipid droplet (fatty acid and cholesterol) accumulation by confocal microscopy and flow cytometry (FACS) revealed no changes with ELTD1 silencing. Silencing was also shown to affect the Notch pathway (downregulating the Notch ligand JAG1 and target gene HES2; upregulating the Notch ligand DLL4) and inducing KIT, a mediator of haematopoietic (HSC) and endothelial stem cell (ESC) maintenance. Signalling experiments revealed that unlike other aGPCRs, ELTD1 does not couple to any canonical GPCR pathways (Gαi, Gαs, Gαq, Gα12/13). ELTD1 overexpression in HUVECS revealed that ELTD1 induces an endothelial tip cell phenotype by promoting sprouting and capillary formation, inhibiting lumen anastomoses in mature vessels and lowering proliferation rate. There was no effect on wound healing or adhesion to angiogenesis associated matrix components. Gene expression changes following ELTD1 overexpression included upregulation of angiogenesis associated ANTRX1 as well as JAG1 and downregulation of migration associated CCL15 as well as KIT and DLL4. In breast cancer, none of the representative breast cancer cell lines screened expressed ELTD1. ELTD1 breast cancer immunohistochemistry revealed higher levels of vascular ELTD1 staining intensity within the tumour stroma contrasted to normal stroma and expression within tumour epithelial cells. Additionally, ELTD1 expression in tumour vessels was differentially expressed between the primary breast cancer microenvironment and that of the matched regional node. Due to the small size of the pilot study population, survival comparisons between the various subgroups did not yield significant results. <strong>Conclusion:</strong> ELTD1 is a novel regulator of endothelial metabolism through its suppression of ACLY and the related citrate transporter SLC25A1. ELTD1 also represses KIT, which is known to mediate haematopoietic and endothelial progenitors stem cell maintenance, a possible mechanism through which endothelial cells maintain terminal endothelial differentiation. ELTD1 does not signal like other adhesion GPCRS with CTF and FL forms of ELTD1 not signalling canonically. Additionally, ELTD1 regulates various functions of endothelial cell behaviour and function, inducing an endothelial tip cell phenotype and is highly evolutionarily conserved. Lastly, ELTD1 is differentially expressed in tumour vessels between primary breast cancer and regional nodal metastases and is also expressed in a small subset of breast cancer cells in vivo despite no cancer cell lines expressing ELTD1. The pilot study investigating ELTD1 in the primary breast cancer and regional involved nodes will be followed up with a larger study including the investigation of ELTD1 in distant metastases.